KEZAR LIFE SCIENCES INC (KZR) Stock News
NASDAQ:KZR - Nasdaq - US49372L2097 - Common Stock - Currency: USD
KZR Latest News, Press Relases and Analysis
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kezar Life Sciences (NASDAQ:KZR) just reported results for the second quarter o...
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024.
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active lupus nephritis (LN) and focus clinical development efforts on zetomipzomib in autoimmune hepatitis (AIH). Last week, the FDA placed a clinical hold on the company’s zetomipzomib Investigational New Drug (IND) application for LN following a review of emerging safety data, including an assessment of four Grade 5 (fatal or death) serious adverse events (SAEs) that occurred du
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in 2025. Kezar also rejected a buyout proposal from Concentra Biosciences.
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kezar Life Sciences (NASDAQ:KZR) just reported results for the first quarter of...
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kezar Life Sciences (NASDAQ:KZR) just reported results for the fourth quarter o...
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
On Friday, Kezar Life Sciences Inc. (NASDAQ:KZR) announced that it was informed via teleconference with the FDA that the zetomipzomib Investigational New Drug (IND) application for lupus nephritis (LN) has been placed on clinical hold. Lupus nephritis is a type of kidney disease caused by systemic lupus erythematosus link (SLE or lupus). Lupus is an autoimmune disease link—a disorder in which the body’s immune system attacks the body’s cells and organs. The action follows Kezar’s communication t
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries.
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology.
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
